Lumasiran

SOURCE: no UK SPC (eMC) record was fetched for this drug (providers.emc is null). The dose above is from the US prescribing information for OXLUMO (lumasiran), Alnylam Pharmaceuticals, label date 2025-12-01 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ef869cb-8ccd-4339-9991-0fab45da1fbd) — verify against UK labelling before use. FULL WEIGHT-BASED TABLE (§2.1, verbatim): body weight less than 10 kg — loading 6 mg/kg once monthly for 3 doses, maintenance 3 mg/kg once monthly beginning 1 month after the last loading dose; 10 kg to less than 20 kg — loading 6 mg/kg once monthly for 3 doses, maintenance 6 mg/kg once every 3 months (quarterly) beginning 1 month after the last loading dose; 20 kg and above — loading 3 mg/kg once monthly for 3 doses, maintenance 3 mg/kg once every 3 months (quarterly) beginning 1 month after the last loading dose. Adults fall in the '20 kg and above' band. MISSED DOSE: 'If a dose is delayed or missed, administer OXLUMO as soon as possible. Resume prescribed monthly or quarterly dosing, from the most recently administered dose.' STRENGTH (§3): injection 94.5 mg/0.5 mL in a single-dose vial. PRACTICAL: for volumes less than 0.3 mL a sterile 0.3-mL syringe is recommended (on a 0.3 mL / 30-unit insulin syringe, 1-unit markings indicate 0.01 mL). No maximum dose is stated in the fetched label. §6.1 and §8.1 text was truncated at the source-fetch limit.

dosePerKg is left null because paediatric dosing in this label is banded by body weight AND differs between loading and maintenance — carrying a single mg/kg number would risk it being applied to the wrong band or phase. VERBATIM §2.1 (Table 1, OXLUMO Weight-Based Dosing Regimen): body weight LESS THAN 10 kg — loading '6 mg/kg once monthly for 3 doses', maintenance '3 mg/kg once monthly, beginning 1 month after the last loading dose'; 10 kg TO LESS THAN 20 kg — loading '6 mg/kg once monthly for 3 doses', maintenance '6 mg/kg once every 3 months (quarterly), beginning 1 month after the last loading dose'; 20 kg AND ABOVE — loading '3 mg/kg once monthly for 3 doses', maintenance '3 mg/kg once every 3 months (quarterly), beginning 1 month after the last loading dose'. 'Dosing is based on actual body weight.' AGE: §8.4 states safety and effectiveness 'have been established in pediatric patients aged birth and older', supported by ILLUMINATE-A (patients 6 years or older and adults), ILLUMINATE-B (patients less than 6 years of age) and ILLUMINATE-C (patients with advanced chronic kidney disease including patients on haemodialysis). No paediatric maximum dose is stated. Verify all under-18 dosing against a children's formulary before prescribing.